Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 18, 2017; 88 (16 Supplement) April 28, 2017

A Randomized, Placebo-Controlled, Blinded, Crossover, Single-Center Study of the Effects of Nuedexta in the Treatment of Neurobehavioral Symptoms of Adults with Autism Spectrum Disorder (P6.213)

Michael Chez, Shawn Kile
First published April 17, 2017,
Michael Chez
1Pediatric Neurology, Sutter Medical Group Roseville CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shawn Kile
1Pediatric Neurology, Sutter Medical Group Roseville CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A Randomized, Placebo-Controlled, Blinded, Crossover, Single-Center Study of the Effects of Nuedexta in the Treatment of Neurobehavioral Symptoms of Adults with Autism Spectrum Disorder (P6.213)
Michael Chez, Shawn Kile
Neurology Apr 2017, 88 (16 Supplement) P6.213;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To determine if Nuedexta(20mg dextromethorphan/10mg quinidine; Avanir Corporation) can improve frontal lobe pseudobulbar irritability in adult autistic patients. A double blind, placebo controlled crossover study was designed to see if there would be statistically significant difference from placebo.

Background: Autism is occurring in 1:68 children, is a lifelong condition, and has no cure. Comorbid irritability is a major problem. Theoretical excessive glutaminergic activation receptor activity in frontal cortex in autistic brain has been described. Nuedexta acts as an NMDA antagonist blocking excessive glutaminergic effect. It is approved for adults with frontal lobe irritability of pseudobulbar type, and many autistic adults may have similar irritability.

Design/Methods: Thirteen autistic adults (ADOS confirmed diagnossi, 11 male, 2 female, average age 21 years) completed a double blinded, placebo-controlled crossover study with interim washout period of 4 weeks separating each treatment vs. placebo arm. Primary outcome measure was the Aberrabt Behavioral Checklist-Irritability (ABC-I), and secondary outocome measures were Overt Aggression Scale (OAS) and total ABC. Clinical Global Impression Scales were also used assessing speech and social behaviors and irritability. Statistical analysis of mean values using a paired-t test was done.

Results: All primary and secondary standardized scales were statistically significant for improvement of irritability and function with Nuedexta over placebo. ABC-I (p=0.021), total ABC (p=0.043) and OAS (p=0.023), and CGI social was significant (p=0.022) and receptive and expressive language CGI showed strong trends (p=0.057 and 0.47 respectively). Washout baseline and initial baseline showed no statistically significant difference in scores, adding to the significance of the above outcomes. Only 1 patient dropped out for side effects in worsened behaviors possibly do to interaction with comedicat, and 1 con-compliant patient dropped out leaving 13/15 completing the 21 week study.

Conclusions: This study shows significant improvement if irritability and improved social function in adult autistic patients in treatment with Nuedexta over placebo. Further studies are warranted with Nuedexta or similar agents in this population.

Study Supported by:

This study was supported by an investigator initiated grant from Avanir Corporation that manufactures Nuedexta. The sponsor provided medication and placebo for the study and patients received this free of charge. Informed consent was obtained from the Sutter Sacramento Institutional Review Board.

Disclosure: Dr. Chez has received research support for activities with UCB, Eisai, and Lundbeck. Dr. Chez has received research support from GW and Marinus. Dr. Kile has received research support from Octapharma.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise